Data Collective Fund IX

Data Collective

Status

ACTIVE

Global HQ

Palo Alto, United States

Countries of investment

United States
Canada
United Kingdom
Israel

Investment stages

Seed
Series A
Series B
Series C
Growth

Industries

Artificial Intelligence
Quantum Computing
Biology
Computational Biology
Space
Energy
Defense
Security
Industrial Software
Climate
DeepTech
Advanced Manufacturing

About
DCVC is a Palo Alto-based venture capital firm focused on backing deep tech companies solving humanity's most consequential challenges. Their focus spans AI, quantum, biology, space, energy, and defense across the United States, Canada, United Kingdom, and Israel. The firm supports deep tech founders from seed through growth stages.

Min check size: $2M
Max check size: $25M
Fund size: Unlock
NPS: Unlock

Investment Thesis

DCVC is a seed to growth stage venture capital firm deploying capital across artificial intelligence, quantum computing, biology, computational biology, space, energy, defense, security, and industrial software sectors. They invest in deep tech companies applying advanced computer science to solve consequential human-scale problems and drive economic growth. The firm differentiates itself through its dedicated Bio and Space specialty funds, technical partner team spanning national labs and universities, and 15+ years of deep tech investing since founding in 2010.

Lead investor: Unlock
Co Invest: Unlock
Number of exits: Unlock
Preferred contact method: Unlock

Manager's Experience

Founded in 2010 by Matt Ocko (Co-Managing Partner, longtime deep tech and computing veteran) and Zack Bogue (Co-Managing Partner). Leadership team includes Rachel Slaybaugh (Partner, former DOE ARPA-E Program Director and UC Berkeley nuclear engineering professor), John Cassidy (Partner, healthcare and biology), Kelly Chen (Partner), Nick Talwar (Partner), Kiran Bhatraju (DCVC Bio), Ali Tamaseb (Principal), and Zafrir Kuplik (Partner Space & Frontier). The firm manages over $4B AUM across multiple funds including flagship DCVC funds, DCVC Bio for computational biology, and DCVC Space. Portfolio includes Pivot Bio, Planet Labs (IPO), Rocket Lab (IPO), Kodiak Robotics, Zymergen (IPO), Recursion Pharmaceuticals (IPO), and Capella Space. Portfolio companies operate in 20+ countries with total combined valuation exceeding $10B.